Background: The levels and fine structure of complex polysaccharides, glycosaminoglycans (GAGs), were determined in segments of the posterior mitral valve leaflet (MVL) taken from 15 patients affected by mitral regurgitation and degenerative disease and were compared with segments from 15 multiorgan donors.Methods: MVL GAGs were analyzed by agarose gel electrophoresis, and by HPLC and fluorophore-assisted carbohydrate electrophoresis to evaluate disaccharide patterns after treatment with chondroitinase ABC.Results: GAGs from the control group were composed of approximately 37% hyaluronic acid and 63% chondroitin sulfate/dermatan sulfate with a charge density of approximately 0.61. Chondroitin sulfate/dermatan sulfate polymers contained approximately 23% of the disaccharide sulfated in position 6 on N-acetyl-galactosamine, ?38% of the 4-sulfated disaccharide and ?2% of the non-sulfated disaccharide (with a 4-sulfated/6-sulfated ratio of 1.7). The total amount of GAGs was 0.66 ?g/mg tissue. The total amount of GAGs in patients suffering from mitral regurgitation and degenerative disease was approximately 51.5% higher (although the difference was not significant, probably because of the low number of subjects enrolled in the study). However, significantly higher hyaluronic acid content (approx. +38%, p<0.05) and lower sulfated GAG content (approx. ?21%, p<0.005) were demonstrated. As a consequence, the total charge density decreased by approximately 23% (p<0.005). This macromodification of GAG composition was also followed by a microalteration of the structure of the sulfated polysaccharides, in particular with a significant decrease in the 4-sulfated disaccharide (and a parallel increase in hyaluronic acid content) with no modification of the percentage of the 6-sulfated and non-sulfated disaccharides (with a significant decrease in the 4-/6-sulfated ratio).Conclusions: We assume that changes in the relative amount and distribution of GAGs in posterior MVL in subjects suffering from mitral regurgitation and degenerative disease are consistent with a decrease in the tension to which these tissues are subjected and with an abnormal matrix microstructure capable of influencing the hydration and of conditioning the mechanical weakness of these pathological tissues.Clin Chem Lab Med 2007;45:361–6.
|Data di pubblicazione:||2007|
|Titolo:||Fine characterization of mitral valve glycosaminoglycans and their modification with degenerative disease.|
|Autore/i:||L., Dainese; G., Polvani; F., Barili; Maccari, Francesca; A., Guarino; F., Alamanni; M., Zanobini; P., Biglioli; Volpi, Nicola|
|Codice identificativo ISI:||WOS:000245357200014|
|Codice identificativo Scopus:||2-s2.0-33947601958|
|Codice identificativo Pubmed:||17378733|
|Citazione:||Fine characterization of mitral valve glycosaminoglycans and their modification with degenerative disease / L., Dainese; G., Polvani; F., Barili; Maccari, Francesca; A., Guarino; F., Alamanni; M., Zanobini; P., Biglioli; Volpi, Nicola. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1434-6621. - STAMPA. - 45 (3)(2007), pp. 361-366.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris